Gyre Therapeutics, Inc. Common Stock
$6.70
Market Cap
$709.37M
Shares Outstanding
106.0M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 31, 2023
Round Lot
100
Locale
US
Day Open
$6.70
Day High
$6.86
Day Low
$6.59
Volume
126.4K
VWAP
$6.72
Prev Close
$6.69
Transactions
--
Acc. Volume
--
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
Gyre Therapeutics, Inc. Common Stock (GYRE) closed the 2026-09-16 session at $6.70, up 0.15% versus the previous close (+0.01). The stock opened at $6.70 and traded between $6.59 and $6.86 during that session. Session trading volume was 126K shares. The volume-weighted average price (VWAP) is $6.72.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
Gyre Therapeutics, Inc. Common Stock has a market capitalization of $709.4 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. GYRE is listed on the XNAS exchange. The company employs approximately 618 people. Gyre Therapeutics, Inc. Common Stock is headquartered in SAN DIEGO, CA. The recorded listing date is 2023-10-31.
On this page you can find market GYRE stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.